PALO ALTO, CA / ACCESSWIRE / September 24, 2024 / Bioz, Inc., a trailblazer in AI-driven research solutions, is proud to announce a transformative partnership with Boston BioProducts, a leading ...

Study resultsMarinomed Biotech AG reports positive clinical results for unique Carragelose eye drops 24.09.2024 / 07:45 CET/CESTThe issuer is solely responsible for the content of this ...

LA JOLLA, CA / ACCESSWIRE / September 23, 2024 / Cenna Biosciences Inc., a privately-held biopharmaceutical company based in La Jolla, California, and focused on developing novel treatments for ...

FDA-approved system enables safe, smooth and accurate fixationDifferentiated hydraulic design gives spinal surgeons greater ...

CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative ...

Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures and venBio·        Funding will support and accelerate development of next-generation multivalent respiratory ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an ...

Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative ...

Kate Shaw, founder and CEO of Innovative Trials, a global clinical trial patient recruitment and retention company, has been crowned a top ‘Woman in Pharma’ at the Pharma Industry Awards UK. She was ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

Biocomposites-sponsored symposium to focus on how to improve outcomes in complex periprosthetic joint infection (PJI) cases, with insights from leading surgeons Abstract by Biocomposites’ researchers ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s Fasenra (benralizumab) ...